Drugs / salvianolic acid A
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03908242 | Apr 2019 | diabetes mellitus | Peking University First Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT03791463 | Dec 2018 → Jan 2019 | — | Peking University First Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT03791125 | Nov 2018 → Mar 2019 | diabetic neuropathy | Peking University First Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | salvianolic acid A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03908242 ↗ |
| Known as | Dan phenolic acid a | ChEMBL registry synonym — accepted as the source's own label CHEMBL457077 ↗ |
| Modality | Small molecule | — CHEMBL457077 ↗ |
| Route | Oral | “Each subject will receive a single oral dose of 90 mg salvianolic acid A.” NCT03791463 ↗ |